1. Catalog
  2. Nodes
  3. path(MESH:"Lewy Body Disease")

path(MESH:"Lewy Body Disease")

Equivalencies: 0 | Classes: 0 | Children: 0 | Explore

Entity

Name
Lewy Body Disease
Namespace
mesh
Namespace Version
20181007
Namespace URL
https://raw.githubusercontent.com/pharmacome/terminology/73ec5665b99a7a4b84edd84bbd46b34fac335358/external/mesh-names.belns

Appears in Networks 4

Nicotinic Acetylcholine Receptors and Nicotinic Cholinergic Mechanisms of the Central Nervous System v1.0.0

Alpha-synuclein oligomers: a new hope v1.0.0

Structural and functional properties of prefibrillar α-synuclein oligomers v1.0.0

mTOR-Related Brain Dysfunctions in Neuropsychiatric Disorders v1.0.0

In-Edges 6

act(p(FPLX:CHRN)) negativeCorrelation path(MESH:"Lewy Body Disease") View Subject | View Object

Nicotinic mechanisms contribute to cognitive function, and the decline of nicotinic mechanisms or loss of nAChRs has been observed in AD, dementia with Lewy bodies, Down syndrome, autism, and Parkinson’s disease (20, 140). PubMed:17009926

Appears in Networks:

p(FPLX:CHRN) negativeCorrelation path(MESH:"Lewy Body Disease") View Subject | View Object

Nicotinic mechanisms contribute to cognitive function, and the decline of nicotinic mechanisms or loss of nAChRs has been observed in AD, dementia with Lewy bodies, Down syndrome, autism, and Parkinson’s disease (20, 140). PubMed:17009926

Appears in Networks:

p(HGNC:SNCA, var("p.Ala30Pro")) increases path(MESH:"Lewy Body Disease") View Subject | View Object

the point mutation in SNCA (A53T) was demonstrated to cause autosomal dominant Parkinson’s disease [126] and several other point mutations (A30P, E46K, H50Q, G51D and A53E) have since been shown to cause familial forms of Parkinson’s disease and dementia with Lewy bodies (DLB) [4, 79, 84, 119, 129, 167]. PubMed:28803412

Appears in Networks:
Annotations
Confidence
Medium

a(HBP:HBP00016) positiveCorrelation path(MESH:"Lewy Body Disease") View Subject | View Object

Parkinson’s disease (PD), Multiple System Atrophy (MSA) and Dementia with Lewy Bodies (DLB) are devastating synucleinopathies. The deposition of filamentous insoluble protein inclusions termed Lewy bodies and Lewy neurites whose main constituent is aggregated α -synuclein (α -syn) characterizes synucleinopathies. PubMed:27075649

Appears in Networks:
Annotations
Confidence
High
MeSH
Lewy Bodies

a(CHEBI:"amyloid-beta") association path(MESH:"Lewy Body Disease") View Subject | View Object

In addition, most DLB patients show most features of AD (i.e., hyperphosphorylated tau deposits and A beta) to various extents PubMed:30061532

Appears in Networks:

p(HGNC:MAPT, pmod(HBP:hyperphosphorylation)) association path(MESH:"Lewy Body Disease") View Subject | View Object

In addition, most DLB patients show most features of AD (i.e., hyperphosphorylated tau deposits and A beta) to various extents PubMed:30061532

Appears in Networks:

Out-Edges 5

path(MESH:"Lewy Body Disease") negativeCorrelation act(p(FPLX:CHRN)) View Subject | View Object

Nicotinic mechanisms contribute to cognitive function, and the decline of nicotinic mechanisms or loss of nAChRs has been observed in AD, dementia with Lewy bodies, Down syndrome, autism, and Parkinson’s disease (20, 140). PubMed:17009926

Appears in Networks:

path(MESH:"Lewy Body Disease") negativeCorrelation p(FPLX:CHRN) View Subject | View Object

Nicotinic mechanisms contribute to cognitive function, and the decline of nicotinic mechanisms or loss of nAChRs has been observed in AD, dementia with Lewy bodies, Down syndrome, autism, and Parkinson’s disease (20, 140). PubMed:17009926

Appears in Networks:

path(MESH:"Lewy Body Disease") positiveCorrelation a(HBP:HBP00016) View Subject | View Object

Parkinson’s disease (PD), Multiple System Atrophy (MSA) and Dementia with Lewy Bodies (DLB) are devastating synucleinopathies. The deposition of filamentous insoluble protein inclusions termed Lewy bodies and Lewy neurites whose main constituent is aggregated α -synuclein (α -syn) characterizes synucleinopathies. PubMed:27075649

Appears in Networks:
Annotations
Confidence
High
MeSH
Lewy Bodies

path(MESH:"Lewy Body Disease") association p(HGNC:MAPT, pmod(HBP:hyperphosphorylation)) View Subject | View Object

In addition, most DLB patients show most features of AD (i.e., hyperphosphorylated tau deposits and A beta) to various extents PubMed:30061532

Appears in Networks:

path(MESH:"Lewy Body Disease") association a(CHEBI:"amyloid-beta") View Subject | View Object

In addition, most DLB patients show most features of AD (i.e., hyperphosphorylated tau deposits and A beta) to various extents PubMed:30061532

Appears in Networks:

About

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.